The stock of Pacific Biosciences of California (NASDAQ:PACB) is a huge mover today! About 1.15M shares traded hands or 7.48% up from the average. Pacific Biosciences of California (NASDAQ:PACB) has declined 28.11% since April 4, 2016 and is downtrending. It has underperformed by 29.20% the S&P500.
The move comes after 7 months positive chart setup for the $640.92M company. It was reported on Nov, 4 by Barchart.com. We have $9.14 PT which if reached, will make NASDAQ:PACB worth $192.28M more.
Pacific Biosciences of California (NASDAQ:PACB) Ratings Coverage
Out of 5 analysts covering Pacific Biosciences of California (NASDAQ:PACB), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Pacific Biosciences of California has been the topic of 11 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald maintained Pacific Biosciences of California (NASDAQ:PACB) on Thursday, November 3 with “Buy” rating. The firm earned “Neutral” rating on Friday, April 15 by M Partners. The stock has “Overweight” rating given by Piper Jaffray on Friday, October 23. The firm earned “Buy” rating on Thursday, August 27 by Maxim Group. The rating was downgraded by Piper Jaffray on Thursday, February 4 to “Neutral”. The company was initiated on Thursday, August 27 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, January 4. First Analysis initiated the stock with “Overweight” rating in Friday, April 15 report. The rating was initiated by CL King with “Buy” on Monday, June 27.
According to Zacks Investment Research, “Pacific Biosciences of California, Inc. is engaged in the development, manufacture and commercialization of its single molecule, real-time, or SMRT technology-an integrated platform for genetic analysis. The SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The Company’s technology platform comprises of the SMRT cells, Phospholinked nucleotides and the PacBio RS (an instrument that conducts, monitors and analyzes single molecule biochemical reactions in real time). Its product will find its application in both research institutions and commercial companies, including genome centers, government and academic institutions, genomic service providers, pharmaceutical companies and agriculture companies. Pacific Biosciences of California, Inc. is headquartered in Menlo Park, California.”
Insitutional Activity: The institutional sentiment increased to 2.12 in 2016 Q2. Its up 0.36, from 1.76 in 2016Q1. The ratio is positive, as 15 funds sold all Pacific Biosciences of California shares owned while 26 reduced positions. 25 funds bought stakes while 62 increased positions. They now own 60.55 million shares or 5.09% more from 57.62 million shares in 2016Q1.
State Board Of Administration Of Florida Retirement System has 44,388 shares for 0% of their US portfolio. Horizon Kinetics Lc holds 12,000 shares or 0% of its portfolio. Invesco Ltd has 12,112 shares for 0% of their US portfolio. Vanguard Gru Incorporated has 2.92M shares for 0% of their US portfolio. Comml Bank Of Montreal Can holds 10,896 shares or 0% of its portfolio. Oberweis Asset Mgmt Incorporated has 13,600 shares for 0.03% of their US portfolio. New York State Common Retirement Fund, a New York-based fund reported 78,800 shares. Blackrock Advsr Limited Company has 1.69 million shares for 0.01% of their US portfolio. Legal General Grp Pcl accumulated 10,288 shares or 0% of the stock. Renaissance Technology Ltd Liability accumulated 0.01% or 404,064 shares. First Allied Advisory Inc holds 0.01% of its portfolio in Pacific Biosciences of California (NASDAQ:PACB) for 16,669 shares. Bnp Paribas Arbitrage last reported 2,961 shares in the company. Jpmorgan Chase Company has 0% invested in the company for 54,910 shares. Aperio Group Limited Liability has 0% invested in the company for 27,301 shares. Arrowpoint Asset Mgmt Ltd Liability Company has 327,408 shares for 0.05% of their US portfolio.
Insider Transactions: Since July 29, 2016, the stock had 0 insider buys, and 2 sales for $337,640 net activity. $168,920 worth of Pacific Biosciences of California (NASDAQ:PACB) was sold by Phillips James Michael.
More notable recent Pacific Biosciences of California (NASDAQ:PACB) news were published by: Fool.com which released: “Pacific Biosciences of California’s Q3 Revenue Soars on Strong Sequencing …” on November 03, 2016, also Reuters.com with their article: “BRIEF-Pacific Biosciences Of California posts Q3 loss $0.19/shr” published on November 02, 2016, Fool.com published: “Why Shares of Pacific Biosciences of California Spiked 19% Today” on April 22, 2016. More interesting news about Pacific Biosciences of California (NASDAQ:PACB) were released by: Fool.com and their article: “Pacific Biosciences of California’s Growth Engine Starting to Gain Momentum” published on August 05, 2016 as well as Prnewswire.com‘s news article titled: “Research Reports Initiation on Biotech Stocks — Pacific Biosciences of …” with publication date: October 10, 2016.
PACB Company Profile
Pacific Biosciences of California, Inc., incorporated in July 14, 2000, designs, develops and makes sequencing systems to help scientists resolve genetically complex problems. The Company’s Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. Based on the Company’s SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.